{"id":19908,"date":"2023-07-07T18:30:15","date_gmt":"2023-07-07T18:30:15","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19908"},"modified":"2023-07-07T18:30:15","modified_gmt":"2023-07-07T18:30:15","slug":"antlera-norrin-wnt-agonist-ant-antibody-enters-clinical-trials-through-a-strategic-partnership-with-eyebio","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/antlera-norrin-wnt-agonist-ant-antibody-enters-clinical-trials-through-a-strategic-partnership-with-eyebio\/","title":{"rendered":"AntlerA Norrin\/Wnt-agonist ANT antibody enters clinical trials through a strategic partnership with EyeBio"},"content":{"rendered":"<div id='av_section_1'  class='avia-section main_color avia-section-default avia-no-border-styling  avia-bg-style-scroll  avia-builder-el-0  avia-builder-el-no-sibling   container_wrap fullsize' style=' '  ><div class='container' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-19908'><div class='entry-content-wrapper clearfix'>\n<div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding first  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><!--Begin ClixTrac.com Banner Code -->\r\n<a href=\"https:\/\/clixtrac.com\/goto\/?311442\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/clixtrac.com\/banner\/311442.jpg\" alt=\"Bio-Rad - Preparing for a Stress-free QC Audit\" title=\"Bio-Rad - Preparing for a Stress-free QC Audit\" border=\"0\" \/><\/a>\r\n<!--End ClixTrac.com Banner Code --><\/p>\n<\/div><\/section><\/div><div class=\"flex_column av_three_fifth  flex_column_div av-zero-column-padding   avia-builder-el-3  el_after_av_one_fifth  el_before_av_one_fifth  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><header class=\"entry-content-header\"><h1 class=\"post-title entry-title\" itemprop=\"headline\">AntlerA Norrin\/Wnt-agonist ANT antibody enters clinical trials through a strategic partnership with EyeBio<\/h1><span class=\"post-meta-infos\">\/ <span class=\"blog-categories minor-meta\">in <a href=\"https:\/\/clinlabint.com\/e-news\/\" rel=\"tag\">E-News<\/a>  <\/span><\/span><\/header>\n<\/div><\/section><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3>AntlerA Norrin\/Wnt-agonist antibody, through a strategic partnership with EyeBio, has entered clinical trials for treatment of retinopathies.<\/h3>\n<p><!--more--><\/p>\n<p>AntlerA previously reported the development of a Norrin\/Wnt-mimetic for treatment of leaky blood vessels in the eye.<\/p>\n<p>\u201cWe are pleased to support EyeBio in the development and advancement of EYE103, a Norrin\/Wnt-mimetic, into the clinic. Built based on AntlerA\u2019s ANT-Pharm platform the tetravalent antibody molecule binds specifically to FZD4\/LRP5 receptors leading to Wnt-signalling and restoration of blood vessel integrity in the eye,\u201d said Dr Sekar Seshagiri, CEO, AntlerA Therapeutics.<\/p>\n<p>He added: \u201cThis is a first-in class molecule for treatment of diabetic retinopathy and several paediatric retinal diseases such as FEVR\/Norrie, Coats, and ROP.\u201d<\/p>\n<p>AntlerA Therapeutics is a regenerative medicines company focused on developing novel protein therapeutics that function by modulating Wnt signalling to harness the regenerative potential of tissue resident stem cells<\/p>\n<\/div><\/section><br \/>\n<div  class='av-social-sharing-box  avia-builder-el-7  el_after_av_textblock  avia-builder-el-last  av-social-sharing-box-minimal '><div class='av-share-box'><h5 class='av-share-link-description av-no-toc '>Share this<\/h5><ul class='av-share-box-list noLightbox'><li class='av-share-link av-social-link-facebook' ><a target=\"_blank\" aria-label=\"Share on Facebook\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/clinlabint.com\/antlera-norrin-wnt-agonist-ant-antibody-enters-clinical-trials-through-a-strategic-partnership-with-eyebio\/&#038;t=AntlerA%20Norrin%2FWnt-agonist%20ANT%20antibody%20enters%20clinical%20trials%20through%20a%20strategic%20partnership%20with%20EyeBio\" aria-hidden=\"false\" data-av_icon=\"\ue8f3\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on Facebook\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on Facebook<\/span><\/a><\/li><li class='av-share-link av-social-link-twitter' ><a target=\"_blank\" aria-label=\"Share on Twitter\" href=\"https:\/\/twitter.com\/share?text=AntlerA%20Norrin%2FWnt-agonist%20ANT%20antibody%20enters%20clinical%20trials%20through%20a%20strategic%20partnership%20with%20EyeBio&#038;url=https:\/\/clinlabint.com\/?p=19908\" aria-hidden=\"false\" data-av_icon=\"\ue8f1\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on Twitter\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on Twitter<\/span><\/a><\/li><li class='av-share-link av-social-link-whatsapp' ><a target=\"_blank\" aria-label=\"Share on WhatsApp\" href=\"https:\/\/api.whatsapp.com\/send?text=https:\/\/clinlabint.com\/antlera-norrin-wnt-agonist-ant-antibody-enters-clinical-trials-through-a-strategic-partnership-with-eyebio\/\" aria-hidden=\"false\" data-av_icon=\"\uf232\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on WhatsApp\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on WhatsApp<\/span><\/a><\/li><li class='av-share-link av-social-link-linkedin' ><a target=\"_blank\" aria-label=\"Share on LinkedIn\" href=\"https:\/\/linkedin.com\/shareArticle?mini=true&#038;title=AntlerA%20Norrin%2FWnt-agonist%20ANT%20antibody%20enters%20clinical%20trials%20through%20a%20strategic%20partnership%20with%20EyeBio&#038;url=https:\/\/clinlabint.com\/antlera-norrin-wnt-agonist-ant-antibody-enters-clinical-trials-through-a-strategic-partnership-with-eyebio\/\" aria-hidden=\"false\" data-av_icon=\"\ue8fc\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on LinkedIn\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on LinkedIn<\/span><\/a><\/li><li class='av-share-link av-social-link-mail' ><a  aria-label=\"Share by Mail\" href='mailto:?subject=AntlerA%20Norrin%2FWnt-agonist%20ANT%20antibody%20enters%20clinical%20trials%20through%20a%20strategic%20partnership%20with%20EyeBio&#038;body=https:\/\/clinlabint.com\/antlera-norrin-wnt-agonist-ant-antibody-enters-clinical-trials-through-a-strategic-partnership-with-eyebio\/' aria-hidden='false' data-av_icon='\ue805' data-av_iconfont='entypo-fontello' title='' data-avia-related-tooltip='Share by Mail'><span class='avia_hidden_link_text'>Share by Mail<\/span><\/a><\/li><\/ul><\/div><\/div><\/p><\/div><div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding   avia-builder-el-8  el_after_av_three_fifth  avia-builder-el-last  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AntlerA Norrin\/Wnt-agonist antibody, through a strategic partnership with EyeBio, has entered clinical trials for treatment of retinopathies.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-19908","post","type-post","status-publish","format-standard","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19908"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=19908"}],"version-history":[{"count":2,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19908\/revisions"}],"predecessor-version":[{"id":19910,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19908\/revisions\/19910"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=19908"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=19908"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=19908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}